Kronos Bio, Inc. (KRON)
NASDAQ: KRON · Real-Time Price · USD
0.903
+0.029 (3.28%)
Nov 22, 2024, 4:00 PM EST - Market closed
Kronos Bio Employees
As of December 31, 2023, Kronos Bio had 63 total employees, including 62 full-time and 1 part-time employees. The number of employees decreased by 34 or -35.05% compared to the previous year.
Employees
63
Change (1Y)
-34
Growth (1Y)
-35.05%
Revenue / Employee
$156,571
Profits / Employee
-$1,358,508
Market Cap
54.49M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 63 | -34 | -35.05% |
Dec 31, 2022 | 97 | 1 | 1.04% |
Dec 31, 2021 | 96 | 33 | 52.38% |
Dec 31, 2020 | 63 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Prenetics Global | 324 |
Singular Genomics Systems | 255 |
Apyx Medical | 252 |
Xtant Medical Holdings | 215 |
Vor Biopharma | 168 |
DBV Technologies | 105 |
Theratechnologies | 103 |
Connect Biopharma Holdings | 81 |
KRON News
- 8 days ago - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - GlobeNewsWire
- 4 weeks ago - Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 6 weeks ago - Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 6 weeks ago - Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - GlobeNewsWire
- 2 months ago - Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - GlobeNewsWire
- 2 months ago - Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer - GlobeNewsWire
- 2 months ago - Kronos Bio Announces Participation in Medical and Investor Conferences in September - GlobeNewsWire
- 4 months ago - Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer - GlobeNewsWire